Niacinamide and Neuroprotection: The Glaucoma Holy Grail

Affiliations

Editorial

Shibal Bhartiya. J Curr Glaucoma Pract. 2022 Sep-Dec.

. 2022 Sep-Dec;16(3):141-143.

doi: 10.5005/jp-journals-10078-1390.

¹ Department of Ophthalmology, Fortis Memorial Research Institute (FMRI) Gurgaon, Haryana, India.

Abstract

How to cite this article: Bhartiya S. Niacinamide and Neuroprotection: The Glaucoma Holy Grail. J Curr Glaucoma Pract 2022;16(3):141-143.

Source of support: Nil Conflict of interest: None

1. Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi: 10.1016/j.ophtha.2014.05.013. - DOI - PubMed
1. Morgan JE. Retina ganglion cell degeneration in glaucoma: an opportunity missed? A review. Clin Exp Ophthalmol. 2012;40(4):364–368. doi: 10.1111/j.1442-9071.2012.02789.x. - DOI - PubMed
1. Williams PA, Harder JM, Foxworth NE, et al. Vitamin B3 modulates mitochondrial vulnerability and prevents glaucoma in aged mice. Science. 2017;355(6326):756–760. doi: 10.1126/science.aal0092. - DOI - PMC - PubMed
1. Tribble JR, Vasalauskaite A, Redmond T, et al. Midget retinal ganglion cell dendritic and mitochondrial degeneration is an early feature of human glaucoma. Brain Commun. 2019;1(1):fcz035. doi: 10.1093/braincomms/fcz035. - DOI - PMC - PubMed
1. Kouassi Nzoughet J, Chao de la Barca JM, Guehlouz K, et al. Nicotinamide deficiency in primary open-angle glaucoma. Invest Ophthalmol Vis Sci. 2019;60(7):2509–2514. doi: 10.1167/iovs.19-27099. - DOI - PubMed